DE69233109D1 - Transgene tiermodelle fur alzheimer-krankheit - Google Patents

Transgene tiermodelle fur alzheimer-krankheit

Info

Publication number
DE69233109D1
DE69233109D1 DE69233109T DE69233109T DE69233109D1 DE 69233109 D1 DE69233109 D1 DE 69233109D1 DE 69233109 T DE69233109 T DE 69233109T DE 69233109 T DE69233109 T DE 69233109T DE 69233109 D1 DE69233109 D1 DE 69233109D1
Authority
DE
Germany
Prior art keywords
promoter
gene promoter
disease
alzheimer
app
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69233109T
Other languages
English (en)
Other versions
DE69233109T2 (de
Inventor
Samuel Wadsworth
Benjamin Snyder
B Reddy
Cha-Mer Wei
Paul Leibowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of DE69233109D1 publication Critical patent/DE69233109D1/de
Application granted granted Critical
Publication of DE69233109T2 publication Critical patent/DE69233109T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
DE69233109T 1992-01-07 1992-12-29 Transgene tiermodelle fur alzheimer-krankheit Expired - Lifetime DE69233109T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81758492A 1992-01-07 1992-01-07
US817584 1992-01-07
US91546992A 1992-07-16 1992-07-16
US915469 1992-07-16
PCT/US1992/011276 WO1993014200A1 (en) 1992-01-07 1992-12-29 Transgenic animal models for alzheimer's disease

Publications (2)

Publication Number Publication Date
DE69233109D1 true DE69233109D1 (de) 2003-07-31
DE69233109T2 DE69233109T2 (de) 2004-05-19

Family

ID=27124190

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69233109T Expired - Lifetime DE69233109T2 (de) 1992-01-07 1992-12-29 Transgene tiermodelle fur alzheimer-krankheit

Country Status (12)

Country Link
US (2) US5720936A (de)
EP (1) EP0620849B1 (de)
JP (3) JPH07506720A (de)
AT (1) ATE243746T1 (de)
AU (1) AU671093B2 (de)
CA (1) CA2127450C (de)
DE (1) DE69233109T2 (de)
DK (1) DK0620849T3 (de)
ES (1) ES2204899T3 (de)
IL (1) IL104304A (de)
PT (1) PT620849E (de)
WO (1) WO1993014200A1 (de)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5586226A (en) * 1990-05-16 1996-12-17 Canon Kabushiki Kaisha Control method and device for a unicolor printer
US5912410A (en) * 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
DE69233774D1 (de) * 1991-01-21 2009-12-10 Elan Pharm Inc Prüfung und Modell für Alzheimers-Krankheit
PT620849E (pt) * 1992-01-07 2003-11-28 Elan Pharm Inc Modelos animais transgenicos para a doenca de alzheimer
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US6264915B1 (en) 1992-09-13 2001-07-24 The President And Fellows Of Harvard College Process for detecting potential carcinogens
US5436153A (en) * 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
WO1994012637A2 (en) * 1992-12-02 1994-06-09 Zymogenetics, Inc. Novel human amyloid protein precursor homologue and kunitz-type inhibitors
ES2155099T3 (es) 1993-10-27 2001-05-01 Elan Pharm Inc Animales transgenicos que albergan alelos app que presentan una mutacion sueca.
JPH07132033A (ja) * 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
CA2182311A1 (en) 1994-01-27 1995-08-03 Karen Hsiao Transgenic non-human mammals with progressive neurologic disease
FR2716460B1 (fr) * 1994-02-21 2002-08-09 Rhone Poulenc Rorer Sa Modèle animal de la maladie d'Alzheimer, préparation et utilisations.
US6025183A (en) * 1994-02-28 2000-02-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Transgenic animal assay system for anti-cholinesterase substances
WO1995034640A1 (en) * 1994-06-13 1995-12-21 Henry Ford Health System A novel neuronal-neonatal gene: neuronatin
CA2198451A1 (en) * 1994-09-01 1996-03-07 Gurparkash Singh Transgenic animal expressing a familial form of human amyloid precursor protein
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
JP2000504202A (ja) * 1994-12-05 2000-04-11 メルク エンド カンパニー インコーポレーテッド 本来のアミロイド前駆体タンパク質欠失トランスジェニック動物
US6187992B1 (en) 1994-12-05 2001-02-13 Merck & Co., Inc. Transgenic mouse having a disrupted amyloid precursor protein gene
US5777194A (en) * 1995-04-26 1998-07-07 Cephalon, Inc. Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
US5777093A (en) * 1995-05-16 1998-07-07 Ramot-University Authority For Applied Research & Industrial Development Ltd. cDNAs associated with ataxia-telangiectasia
US5728807A (en) * 1995-05-16 1998-03-17 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Mutated proteins associated with ataxia-telangiectasia
US5858661A (en) 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
US6187991B1 (en) 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
CA2221986A1 (en) * 1995-06-07 1996-12-19 Athena Neurosciences, Inc. Method for identifying alzheimer's disease therapeutics using transgenic animal models
AU6168396A (en) * 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Method for identifying alzheimer's disease therapeutics usin g transgenic animal models
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US5894078A (en) * 1996-02-26 1999-04-13 Advanced Bioconcept, Inc. Transgenic mouse expressing C-100 app
US6140309A (en) * 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
WO1997046664A1 (en) * 1996-06-06 1997-12-11 University Of Washington Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
EP0954574A2 (de) 1996-07-01 1999-11-10 Jim A. Wright Oligonukleotide aus nicht-translatierten regionen von konstitutiven genen und verfahren zu deren verwendung zur regulierung des zellwachstums
WO1998003644A1 (en) * 1996-07-24 1998-01-29 Novartis Ag Transgenic animal model for alzheimer disease
US20010016951A1 (en) 1996-07-24 2001-08-23 Bernd Sommer Transgenic animal model for alzheimer disease
WO1998003643A2 (en) * 1996-07-22 1998-01-29 Smithkline Beecham Pharma Gmbh Transgenic animals with mutant human app or a4ct sequences
JP2000517185A (ja) 1996-08-29 2000-12-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 新規なメタロプロテアーゼファミリーｋｕｚ
US6566089B1 (en) * 1996-09-04 2003-05-20 Tularik Inc. Cell-based drug screens for regulators of gene expression
WO1998015172A2 (en) * 1996-10-10 1998-04-16 Institut Pasteur Transgenic or mutated animal as model for a neuron deficit
US5898094A (en) * 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
US7973156B2 (en) 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
DK1045918T3 (da) 1998-01-12 2008-12-08 Pedro Jose G protein-relaterede kinasemutanter i essentiel hypertension
CA2321934C (en) * 1998-02-25 2012-02-21 Paul Q. Anziano Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6548261B1 (en) 1998-12-30 2003-04-15 Case Western Reserve University Alzheimer model for drug screening
EP1026251A3 (de) * 1999-02-03 2000-09-06 Pfizer Products Inc. Transgene Tiere welche das menschliche p25 Gen exprimieren
US6374130B1 (en) 1999-04-06 2002-04-16 Eric M. Reiman Methods for tracking the progression of Alzheimer's disease identifying treatment using transgenic mice
US6670195B1 (en) 1999-05-26 2003-12-30 New York University Mutant genes in Familial British Dementia and Familial Danish Dementia
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6787318B1 (en) 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6541244B1 (en) * 1999-06-07 2003-04-01 Cedars-Sinai Medical Center Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
US7569660B1 (en) 1999-06-09 2009-08-04 The University Of Chicago Recombinant prion-like proteins and materials comprising same
US6875582B1 (en) 1999-08-19 2005-04-05 Omniscience Pharmaceuticals, Inc. Methods and targets of antibiotic resistance
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
AU2288601A (en) 1999-12-23 2001-07-03 Millennium Pharmaceuticals, Inc. P2Y12 receptor
NZ520065A (en) 2000-01-12 2006-02-24 Univ Yale Nogo receptor-mediated blockade of axonal growth
US7385106B2 (en) 2000-01-24 2008-06-10 Ramot At Tel Aviv University Ltd. Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US6982361B1 (en) * 2000-02-25 2006-01-03 The Regents Of The University Of California Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal
DE60124080T2 (de) 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
EP1274720A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin enthaltende fusionsproteine
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
JP2004502664A (ja) * 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病処置用化合物
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
EP1666452A2 (de) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Verbindungen zur Behandlung der Alzheimerischen Krankheit
HUP0300810A2 (hu) 2000-07-20 2003-08-28 M.G.V.S. Ltd. Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20030087286A1 (en) * 2000-09-06 2003-05-08 Hodge Timothy A. Isolation of eukaryotic genomic DNA using magnetically responsive solid functionalized particles
US7494817B2 (en) * 2000-09-06 2009-02-24 Transnet Yx, Inc. Methods for genotype screening using magnetic particles
US20050272085A1 (en) * 2000-09-06 2005-12-08 Hodge Timothy A Methods for forensic and congenic screening
EP1978110B1 (de) * 2000-09-06 2010-05-26 Transnetyx, Inc. Computer-basiertes Verfahren und System zum Screenen von genomischer DNS
US20050266494A1 (en) * 2000-09-06 2005-12-01 Hodge Timothy A System and method for computer network ordering of biological testing
US20030082605A1 (en) * 2000-09-06 2003-05-01 Hodge Timothy A. Genomic DNA detection method and system thereof
US20050239125A1 (en) * 2000-09-06 2005-10-27 Hodge Timothy A Methods for genotype screening
US6900367B2 (en) * 2000-09-29 2005-05-31 Novartis Transgenic Drosophila melanogaster expressing a β42 in the eye
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20020170078A1 (en) * 2001-03-08 2002-11-14 Isabelle Mansuy Calcineurin-related transgenic mammals, compositions and methods
US7081561B2 (en) 2001-03-16 2006-07-25 The Regents Of The University Of California Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
ATE396174T1 (de) * 2001-06-01 2008-06-15 Elan Pharm Inc Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
MXPA03011521A (es) 2001-06-13 2004-03-18 Elan Pharm Inc Aminadioles para tratamiento de enfermedad de alzheimer.
US6982264B2 (en) * 2001-06-27 2006-01-03 Elan Pharmaceuticals, Inc. Substituted alcohols useful in treatment of Alzheimer's disease
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
CA2453451A1 (en) * 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Aminediols for the treatment of alzheimer's disease
US7067542B2 (en) * 2001-07-10 2006-06-27 Pharmacia & Upjohn Company Diaminediols for the treatment of Alzheimer's disease
US7297553B2 (en) * 2002-05-28 2007-11-20 Nanosphere, Inc. Method for attachment of silylated molecules to glass surfaces
CA2455497A1 (en) * 2001-08-31 2003-03-06 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20060014186A1 (en) * 2001-09-04 2006-01-19 Hodge Timothy A Methods for genotype screening of a strain disposed on an adsorbent carrier
BR0213139A (pt) 2001-10-04 2004-08-10 Elan Pharm Inc Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
NZ533107A (en) * 2001-11-08 2007-04-27 Upjohn Co N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
WO2003043618A2 (en) * 2001-11-19 2003-05-30 Elan Pharmaceuticals, Inc. Amino diols useful in the treatment of alzheimer's disease
US8178128B2 (en) 2001-12-05 2012-05-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticles containing polymeric nucleic acid homologs
EP2277888A3 (de) 2001-12-21 2011-04-27 Human Genome Sciences, Inc. Fusionsprotein von Albumin und Erythropoietin
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216370A1 (en) * 2002-02-27 2003-09-09 Merck And Co., Inc. Assays to monitor amyloid precursor protein processing
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004058686A1 (en) * 2002-04-30 2004-07-15 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer’s disease
UY27967A1 (es) * 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
EP1558737A4 (de) 2002-10-18 2008-06-11 Lg Life Sciences Ltd Mit krebserkrankungen assoziierte genfamilien
AU2003293155A1 (en) * 2002-11-27 2004-06-23 Elan Pharmaceutical, Inc. Substituted ureas and carbamates
US7341847B2 (en) * 2003-04-02 2008-03-11 Agency For Science, Technology And Research Promoter construct for gene expression in neuronal cells
CA2522805A1 (en) * 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. Phenacyl 2-hydroxy-3-diaminoalkanes
EP1615892A2 (de) 2003-04-21 2006-01-18 Elan Pharmaceuticals, Inc. Benzamid-2-hydroxy-3-diaminoalkane
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
BRPI0410348A (pt) 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
CA2526900C (en) 2003-05-19 2015-11-24 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in lewy body disease
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20060014790A1 (en) * 2004-01-21 2006-01-19 Varghese John Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
WO2005087215A1 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
CA2556826A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
WO2005087751A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
JP2007528402A (ja) * 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
SE0400707D0 (sv) 2004-03-22 2004-03-22 Bioarctic Neuroscience Ab Transgenic animal model
KR100574544B1 (ko) * 2004-04-01 2006-04-27 주식회사 뉴로테크 돌연변이 βＣＴＦ99를 발현하는 알츠하이머병 유발형질전환 마우스
US7544855B2 (en) * 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
JP2007538024A (ja) * 2004-05-19 2007-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物
JP4476050B2 (ja) * 2004-06-30 2010-06-09 株式会社ニデック 視野計
JP2008505929A (ja) * 2004-07-09 2008-02-28 エラン ファーマシューティカルズ，インコーポレイテッド オキシム誘導体ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
US7385085B2 (en) * 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
US8383637B2 (en) * 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) * 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) * 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
GB0419124D0 (en) * 2004-08-27 2004-09-29 Proteome Sciences Plc Methods and compositions relating to Alzheimer's disease
CA2577392A1 (en) * 2004-08-27 2006-03-09 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
EP2332408B1 (de) 2005-02-17 2013-11-13 Biogen Idec MA Inc. Behandlung neurologischer Störungen
EP1746092A1 (de) 2005-07-22 2007-01-24 Exonhit Therapeutics SA Verbindungen und Methoden zur Behandlung von Erkrankungen die in Verbindung mit beta-Amyloidpeptiden stehen
US20080293680A1 (en) * 2005-08-03 2008-11-27 Stefan Peters Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II
CA2618019A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for the treatment of alzheimer's disease
EP1915353A2 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Isophthalsäurediamide zur behandlung der alzheimer erkrankung
US20100144681A1 (en) * 2005-08-11 2010-06-10 Klaus Fuchs Compounds for the treatment of alzheimer's disease
CA2618013A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Beta-secretase inhibitors for use in the treatment of alzheimer's disease
EP1937638A1 (de) * 2005-10-12 2008-07-02 Elan Pharmaceuticals Inc. Verfahren zur behandlung von amyloidose unter verwendung von aspartylproteaseinhibitor- arylcyclopropylderivaten
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
WO2007088418A1 (en) 2006-01-31 2007-08-09 Multi Gene Vascular Systems, Inc. Drug-eluting intravascular prostheses and methods of use
US7776882B2 (en) * 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7932261B2 (en) * 2006-02-06 2011-04-26 Janssen Pharmaceutica Nv Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
US7868022B2 (en) * 2006-02-06 2011-01-11 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008019368A2 (en) * 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
US9127084B2 (en) 2006-09-14 2015-09-08 Medgenics Medical Israel Ltd. Long lasting drug formulations
CA2664318C (en) 2006-09-14 2017-05-23 Andrew L. Pearlman Long lasting drug formulations
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
EP2862581B1 (de) 2006-10-12 2021-08-11 BHI Limited Partnership Verfahren, Verbindungen, Zusammensetzungen und Medien zur Abgabe von 3-Amino-1-Propanesulfonsäure
PL381605A1 (pl) 2007-01-25 2008-08-04 Instytut Biologii Doświadczalnej Im. M. Nenckiego Polskiej Akadmii Nauk Transgeniczne zwierzę i sposób jego otrzymywania
EP2134863B1 (de) 2007-03-13 2014-05-21 The Children's Hospital Of Philadelphia Genetische veränderungen auf chromosom 16 und verfahren zur verwendung davon bei der diagnose von typ-1-diabetes
US7943590B2 (en) 2007-03-16 2011-05-17 Multi-Gene Vascular Systems Ltd. Compositions and methods for treating ophthalmic disorders
EP2514766A3 (de) 2007-03-29 2013-06-05 Technion Research & Development Foundation Ltd. Antikörper, Verfahren und Kits zur Diagnose und Behandlung von Melanomen
EP2191001B1 (de) 2007-04-09 2016-06-08 University of Florida Research Foundation, Inc. Raav-vektorzusammensetzungen mit tyrosin-modifizierten capsidproteinen und verwendungsverfahren
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
WO2009007300A2 (en) 2007-07-06 2009-01-15 Boehringer Ingelheim International Gmbh Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
BRPI0906625A2 (pt) * 2008-01-28 2015-07-14 Janssen Pharmaceutica Nv Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
NZ586830A (en) * 2008-01-29 2012-02-24 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
CA2714713C (en) 2008-02-19 2018-02-27 The Children's Hospital Of Philadelphia Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
EP2116260A1 (de) 2008-04-16 2009-11-11 Freie Universität Berlin Screening-Verfahren von geeigneten Wirkstoffen zur Vorbeugung und Behandlung von Alzheimer (AD)
WO2009140679A2 (en) 2008-05-16 2009-11-19 The Children's Hospital Of Philadelphia Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
US8871460B2 (en) 2009-11-09 2014-10-28 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
KR20200047642A (ko) 2010-04-23 2020-05-07 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 레베르 선천성 흑내장-1(lca1)의 치료를 위한 재조합 아데노-관련된 바이러스-구아닐레이트 사이클라제 조성물 및 방법
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
AU2013235422B2 (en) 2012-03-19 2016-12-15 Buck Institute For Research On Aging APP specific BACE inhibitors (ASBIs) and uses thereof
JP6471100B2 (ja) 2013-02-12 2019-02-13 バック・インスティテュート・フォー・リサーチ・オン・エイジング Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン
TW201522629A (zh) 2013-10-24 2015-06-16 Medgenics Medical Israel Ltd 提供治療多肽之持續遞送的微器官及其使用方法
WO2016077078A1 (en) 2014-10-29 2016-05-19 The Children's Hospital Of Philadelphia Diagnosis and treatment of genetic alterations associated with eosinophilic esophagitis
US10683552B2 (en) 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
EP3626832A3 (de) 2014-11-25 2020-05-13 The Brigham and Women's Hospital, Inc. Verfahren zur identifizierung und behandlung einer person mit einer prädisposition für eine kardiometabolische krankheit oder eine davon betroffene person
WO2017035017A1 (en) 2015-08-21 2017-03-02 The Children's Hospital Of Philadelphia Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
AU2016311502B2 (en) 2015-08-27 2019-07-18 Nantneuro, Llc Compositions for app-selective bace inhibition and uses therfor
CN109563089B (zh) 2016-05-12 2023-06-16 巴克老年研究所 促进app正常加工的化合物
EP4286405A1 (de) * 2021-01-28 2023-12-06 Abrain Gentherapie zur behandlung neurodegenerativer erkrankungen

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3636991A1 (de) * 1986-03-03 1987-09-24 Transgene Gmbh Verfahren zur uebertragung organischer und/oder anorganischer substanzen auf ei- und/oder somazellen von tieren sowie entsprechende zusammensetzungen
AU7879987A (en) * 1986-08-28 1988-03-24 Immunex Corp. Expression of heterologous proteins by transgenic lactating mammals
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US5220013A (en) * 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
EP0332640A1 (de) * 1986-11-17 1989-09-20 California Biotechnology, Inc. Rekombinantes alzheimer-amyloidprotein
US4994384A (en) * 1986-12-31 1991-02-19 W. R. Grace & Co.-Conn. Multiplying bovine embryos
EP0832981A1 (de) * 1987-02-17 1998-04-01 Pharming B.V. DNA-Sequenzen die Proteine zwecks effizienter Abscheidung zur Milchdrüse leiten
AU3056289A (en) * 1988-01-13 1989-08-11 Mclean Hospital Corporation, The Genetic constructs containing the alzheimer brain amyloid gene
AU6275190A (en) * 1989-09-14 1991-04-18 Norina Bautechnik Gmbh Floor with electrical resistance heating
US5221607A (en) * 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
EP0451700A1 (de) * 1990-04-10 1991-10-16 Miles Inc. Rekombinante APP Minigene zur Expression in Transgen-Mäusen als Alzheimer-Krankheitsmuster
ATE260974T1 (de) * 1990-06-15 2004-03-15 Scios Inc Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
EP0550675A1 (de) * 1990-09-28 1993-07-14 Cephalon, Inc. Alzheimeramyloidvorläufersgen enthaltende transgentiere
DE69233774D1 (de) * 1991-01-21 2009-12-10 Elan Pharm Inc Prüfung und Modell für Alzheimers-Krankheit
US5672805A (en) * 1991-07-18 1997-09-30 The Regents Of The University Of California Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
AU2765992A (en) * 1991-10-03 1993-05-03 Indiana University Foundation Method for screening for alzheimer's disease
PT620849E (pt) * 1992-01-07 2003-11-28 Elan Pharm Inc Modelos animais transgenicos para a doenca de alzheimer
EP0561087B1 (de) * 1992-03-20 1999-08-04 N.V. Innogenetics S.A. Mutierte Form von dem Beta-Amyloidprecursor Proteine Gen
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
EP0667959B1 (de) * 1992-10-26 2003-08-13 Elan Pharmaceuticals, Inc. Verfahren zur Identifizierung von Hemmstoffe der Produktion des beta-Amyloidpeptids
WO1994023049A2 (en) * 1993-04-02 1994-10-13 The Johns Hopkins University The introduction and expression of large genomic sequences in transgenic animals
ES2155099T3 (es) * 1993-10-27 2001-05-01 Elan Pharm Inc Animales transgenicos que albergan alelos app que presentan una mutacion sueca.
WO1995014769A1 (en) * 1993-11-29 1995-06-01 University Of South Florida TRANSGENIC MOUSE PREPARED USING YEAST ARTIFICIAL CHROMOSOMES (YACs) AND HOMOLOGOUS RECOMBINATION

Also Published As

Publication number Publication date
JP2004089187A (ja) 2004-03-25
JP2007267742A (ja) 2007-10-18
EP0620849B1 (de) 2003-06-25
PT620849E (pt) 2003-11-28
US5811633A (en) 1998-09-22
AU671093B2 (en) 1996-08-15
JPH07506720A (ja) 1995-07-27
CA2127450A1 (en) 1993-07-22
US5720936A (en) 1998-02-24
EP0620849A1 (de) 1994-10-26
ES2204899T3 (es) 2004-05-01
AU3336093A (en) 1993-08-03
CA2127450C (en) 2007-04-17
WO1993014200A1 (en) 1993-07-22
DK0620849T3 (da) 2003-10-20
IL104304A (en) 2004-09-27
DE69233109T2 (de) 2004-05-19
IL104304A0 (en) 1993-05-13
ATE243746T1 (de) 2003-07-15

Similar Documents

Publication Publication Date Title
ATE243746T1 (de) Transgene tiermodelle fur alzheimer-krankheit
Fischer et al. The development of small primate models for aging research
Cai et al. Nuclear ferritin protects DNA from UV damage in corneal epithelial cells
Schwarz et al. Pax2/5 and Pax6 subdivide the early neural tube into three domains
US8232450B1 (en) Purple transgenic fluorescent ornamental fish
Hemachandra Reddy et al. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease
FR2814642A1 (fr) Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
Seo et al. Biology of epidermal and hair pigmentation in cattle: a mini‐review
CN104450602A (zh) 非人哺乳动物神经精神疾病动物模型及其制备方法和用途
Noh et al. Genomic cloning of mud loach Misgurnus mizolepis (Cypriniformes, Cobitidae) β-actin gene and usefulness of its promoter region for fish transgenesis
Hansen et al. Influence of season and environment on adult neurogenesis in the central olfactory pathway of the shore crab, Carcinus maenas
IT1246018B (it) Metodo per la conservazione di organismi animali utilizzati nella pesca, in laboratorio, nella lotta biologica in agricoltura: contenitore e confezionamento relativi.
Shackelford et al. Regulation of apolipoprotein A1 synthesis in avian muscles.
Ozkanlar et al. Effects of photoperiod on thyroid gland development and function in growing chicks: a biochemical and morphometric study
Ross et al. Alligator mississippiensis
Daume et al. Patterns of tubb2b promoter-driven fluorescence in the forebrain of larval Xenopus laevis
Johnston et al. The roles of Bcl-x L in modulating apoptosis during development of Xenopus laevis
Pfeiler et al. Ontogenetic changes in proteins and isozyme expression in larval and juvenile bonefish (Albula)
Tyshko et al. Analysis of the intensity of apoptosis in rat organs at various stages of ontogeny
Durand et al. Influence of temperature on the development of Proteus anguinus (Caudata: Proteidae) and relation with its habitat in the subterranean world
Mekhtiev et al. Antimutagenic activity of serotoninergic system and underlying mechanisms in fry of sturgeon and goldfish
Jacobs Localisation of neural progenitor cells and the influence of age in the African turquoise killifish
Hall et al. Neuronal intermediate filament expression during neurite outgrowth from explanted goldfish retina: effect of retinoic acid
Liu et al. Increased light exposure alleviates one form of photoreceptor degeneration marked by elevated calcium in the dark
Ono et al. Changes in brain metallothionein and zinc during development in transgenic mice

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 620849

Country of ref document: EP